Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

ASCO

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma https://meetings.asco.org/abstracts-presentations/226084

Effect of a novel expansion process on tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype https://meetings.asco.org/abstracts-presentations/226455